This summary was created by AI, based on 1 opinions in the last 12 months.
The reviews from experts indicate that despite rapid growth, the stock has been trading sideways since 2022. The company delivered mixed numbers in February, and the forecast was considered confusing, although revenue and earnings projections were up. Overall, the stock's performance seems to be not fully reflecting the company's growth.
Progyny is a OTC stock, trading under the symbol PRGNY-Q on the (). It is usually referred to as or PRGNY-Q
In the last year, 1 stock analyst published opinions about PRGNY-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Progyny.
Progyny was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Progyny.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year 1 stock analyst on Stockchase covered Progyny. The stock is worth watching.
On , Progyny (PRGNY-Q) stock closed at a price of $.
A fertility benefits management company for employees. Rapid growth is not reflected in the stock. Been sideways since 2022, and delivered mixed numbers in February while the forecast was confusing though revenue and earnings projections were up.